🇺🇸 FDA
Pipeline program

ML-004 (IR)/(ER) tablet

ML-004-003

Phase 2 small_molecule active

Quick answer

ML-004 (IR)/(ER) tablet for Autism Spectrum Disorder is a Phase 2 program (small_molecule) at MapLight Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
MapLight Therapeutics
Indication
Autism Spectrum Disorder
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials